The most popular medications for high cholesterol are statins, and two dominate by a wide margin: rosuvastatin (Crestor) and atorvastatin (Lipitor). In the most recent prescription data available, rosuvastatin topped the list with more than 17 million prescriptions filled in a single year, with atorvastatin close behind. Both are available as low-cost generics, and current guidelines from the American Heart Association and American College of Cardiology confirm statins as the first-line treatment for lowering cholesterol and reducing heart disease risk.
Why Statins Are the Standard Treatment
Statins work by blocking an enzyme your liver needs to produce cholesterol. When that enzyme is suppressed, your liver pulls more LDL (“bad”) cholesterol out of your bloodstream to compensate, which lowers your levels. This mechanism has been studied for decades, and statins remain the most thoroughly tested class of cholesterol drugs in existence.
The 2026 ACC/AHA guidelines recommend statins as the go-to medication for both people who already have cardiovascular disease and those at elevated risk of developing it. How aggressively your doctor treats depends on your 10-year risk of a heart attack or stroke, calculated from factors like age, blood pressure, cholesterol levels, diabetes status, smoking history, and kidney function. People at high risk (10% or greater over 10 years) are typically started on high-intensity statin therapy aimed at cutting LDL cholesterol by 50% or more. Those at intermediate risk may start on a moderate-intensity dose targeting a 30% to 49% reduction.
Rosuvastatin vs. Atorvastatin
These two medications account for the vast majority of cholesterol prescriptions worldwide, and they’re more similar than they are different. Both are high-intensity statins capable of large LDL reductions, and both are available as generics at roughly $10 per prescription. When atorvastatin first went generic in 2011, it cost around $159 per fill. By 2022 that had dropped to about $10.40, making cost a non-issue for most patients.
The key clinical difference is that rosuvastatin binds more tightly to the enzyme it targets, which may give it a slight edge in raw potency at equivalent doses. However, that same property appears to carry a slightly higher risk of new-onset diabetes compared to atorvastatin. A secondary analysis of a randomized trial published in The BMJ found this association, though the absolute risk remains small. In practice, doctors choose between the two based on individual patient factors, and switching from one to the other is common if side effects arise.
Statin Side Effects: What the Data Shows
Muscle pain is the side effect people worry about most with statins, and it’s the most common reason people stop taking them. But the actual numbers are surprising. A large 2022 meta-analysis published in The Lancet, pooling data from 19 placebo-controlled trials, found that 27.1% of people on statins reported muscle pain or weakness, compared to 26.6% of people taking a placebo. That tiny gap means only about 1 in 15 reports of muscle symptoms on a statin are actually caused by the drug. The rest are coincidental aches that people attribute to their medication.
During the first year of treatment, statins produced a 7% relative increase in muscle symptoms compared to placebo. That’s real but modest, and it means the vast majority of people who experience muscle discomfort while taking a statin would have felt the same way without it. For the small number of people who do have genuine statin-related muscle problems, switching to a different statin or adjusting the dose usually resolves the issue.
Non-Statin Options When Statins Aren’t Enough
Some people can’t tolerate any statin, and others need additional cholesterol lowering beyond what a statin alone can achieve. Several non-statin medications fill those gaps.
Ezetimibe is the most common add-on. It works differently from statins by blocking cholesterol absorption in the intestine rather than reducing production in the liver. It’s a daily pill, available as a generic, and is often combined with a statin when LDL levels remain above target. On its own, ezetimibe produces a more modest reduction than statins, but the combination of the two is more effective than either alone.
Bempedoic acid (Nexletol) is a newer oral option that targets a step in the same cholesterol-production pathway as statins but acts earlier in the process. In real-world data presented through the American Heart Association, the combination of bempedoic acid plus ezetimibe lowered LDL cholesterol by about 28% at three months and 22% at 12 months. This combination is particularly useful for people who are statin-intolerant, since bempedoic acid doesn’t activate in muscle cells and avoids the muscle-related side effects that drive some people away from statins.
Injectable Cholesterol Medications
For people with very high cholesterol that resists oral medications, or those with genetic conditions like familial hypercholesterolemia, injectable treatments offer powerful LDL reductions.
PCSK9 inhibitors (sold as Repatha and Praluent) are injections given every two to four weeks. They work by blocking a protein that normally destroys the receptors your liver uses to clear LDL from the blood. With more receptors intact, your liver pulls significantly more cholesterol out of circulation. In a large Italian registry study, patients with familial hypercholesterolemia saw LDL reductions of about 58% after two years of treatment, bringing average levels down to around 80 mg/dL. These drugs are typically reserved for patients who haven’t reached their cholesterol goals on maximum statin therapy plus ezetimibe, or who can’t tolerate statins at all.
Inclisiran (Leqvio) is a newer injectable that works through a different mechanism, silencing the gene that produces the same PCSK9 protein. Its main advantage is convenience: after an initial dose and a follow-up at three months, it’s given just twice a year. In FDA clinical trials, inclisiran reduced LDL cholesterol by 48% to 52% compared to placebo over about 17 months. The twice-yearly dosing schedule makes it appealing for people who struggle with daily pills or more frequent injections.
How Doctors Decide What to Prescribe
The decision starts with your cardiovascular risk level, not just your cholesterol number. The current guidelines use a framework that calculates your 10-year risk of a heart attack or stroke, then adjusts based on personal factors the calculator might miss, such as family history, inflammatory markers, or ethnic background. In borderline cases, a coronary artery calcium (CAC) scan can help clarify whether statin therapy is worth starting.
For most people, that process leads to a generic statin. Rosuvastatin or atorvastatin at a moderate or high dose will be the first prescription. If that doesn’t bring LDL down far enough, ezetimibe is typically added. If the combination still falls short, or if statin intolerance is an issue, bempedoic acid or one of the injectables enters the picture. People who have already had a heart attack or stroke face stricter targets: the latest guidelines recommend getting LDL below 55 mg/dL for those at very high risk of another event.
Lifestyle changes run alongside every medication decision. The guidelines are explicit that diet, exercise, and weight management are foundational, not optional add-ons. A statin works best when it’s paired with reduced saturated fat intake, regular physical activity, and not smoking. No pill fully compensates for a diet high in processed food and saturated fat.